Standard treatment for advanced endometrial cancer may soon change. A study found that people with advanced or recurrent endometrial cancer who received immunotherapy with chemotherapy had better outcomes than those who had chemotherapy alone.
https://www.facingourrisk.org/XRAY/immunotherapy-improves-advanced-endometrial-cancer-outcomes
In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone.
Current research points towards ovarian cancer beginning in the fallopian tube and not in the ovary itself.
This is where PROTECTOR comes in, with the theory being that removing the tube alone will help prevent cancer while being able to preserve fertility and avoid early menopause which comes with symptoms and long term health issues like hot flushes, sweats, mood changes, thinning of the bones, memory problems, higher risk of heart disease, and reduced libido.
A simple test using saliva or blood to determine if there is some type of mutation that will predispose you to certain types of cancers.
Preventative screening just part of our lives….
What do you need to do to get yourself from getting a cancer…
Understanding what it means and educating yourself…
It’s a Family diagnosis.
Open communication is important.
Knowledge is power.
Why would you not want to know???
Uptake of RRS before 50 years of age was low, and RRS was rarely undertaken in association with surgical treatment of CRC.
Uptake of RRS aligned poorly with gene- and age-associated risk estimates for endometrial or ovarian cancer that were published recently from PLSD and did not correspond well with current clinical guidelines.
The reasons should be clarified. Decision-making on opting for or against RRS and its timing should be better aligned with predicted risk and mortality for endometrial and ovarian cancer in Lynch syndrome to improve outcomes.
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00240-6/fulltext
This Review provides an overview of the known syndromes and genes, genetic testing, and clinical management of patients with polyposis, and recent advances and challenges in the field of gastrointestinal polyposis.
The European Health Data Space (EHDS) seeks to address key challenges
facing healthcare systems in Europe resulting from lack of access to health
data, and is designed to boost Europe’s competitiveness on the global
stage. If passed, individuals will have access to, and control over, their
digital health data from anywhere within the EU. It will also make large,
anonymised datasets available for research, innovation, and policymaking.
When compared to European countries such as Denmark, that has a
similar-sized population, Ireland has traditionally had less access to
health research funding. This coupled with a lack of integrated health data
availability has meant that finding Irish patients to take part in clinical trials
is difficult.
By harnessing the value of health data, the EHDS has potential
to enable better healthcare for patients, and improve the lives of the family
teams that care for them. Ireland has a unique set of capabilities that can
contribute to the vision of the EHDS and support the needs of patients,
healthcare professionals, and others working on the frontline of healthcare
at home and across Europe.
Awareness will need to be raised among key stakeholders—the healthcare
system, patients, citizens—and support provided to help them prepare for
the far-reaching changes ahead. Their engagement will in no small part
determine Ireland’s ability to make the leap from where it is today to full-
scale implementation of the EHDS in 2025.
